NextCure

$11.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.49 (+4.47%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell NextCure and other stocks, options, and ETFs commission-free!

About NXTC

NextCure, Inc. Common Stock, also called NextCure, is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD. The listed name for NXTC is NextCure, Inc. Common Stock.

CEO
Michael S. Richman
Employees
69
Headquarters
Beltsville, Maryland
Founded
2015
Market Cap
315.21M
Price-Earnings Ratio
Dividend Yield
Average Volume
328.95K
High Today
$11.76
Low Today
$10.90
Open Price
$10.96
Volume
362.55K
52 Week High
$70.98
52 Week Low
$7.91

Collections

NXTC Earnings

-$4.46
-$2.86
-$1.27
$0.33
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like